Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression MESHD

    Authors: meizhu chen; changli tu; Cuiyan Tan; Xiaobin Zheng; xiaohua wang; jian wu; Yiying Huang; zhenguo wang; yan yan; zhonghe li; hong shan; Jing Liu; jin huang

    doi:10.1101/2020.04.06.20054890 Date: 2020-04-11 Source: medRxiv

    Abstract Background COVID-19 is a new and highly contagious respiratory disease MESHD that has caused global spread, high case fatality rate in severe patients, and a huge medical burden due to invasive mechanical ventilation. The current diagnosis and treatment guidelines are still need to be improved, and more excellent clinical experience is needed to provide reference. Methods We analyzed and summarized clinical data of 97 confirmed COVID-19 adult TRANS patients (including 26 severe cases) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 17, 2020 to March 10, 2020,included laboratory examination results, imaging findings, treatment effect, prognosis , etc, in order to put forward prediction index of severe COVID-19 patients, principles of early intervention and methylprednisolone usages in COVID-19 patients. Results 1. Hypoxemia HP, hyperlactic acid, hypoproteinemia MESHD hypoproteinemia HP, and hypokalemia MESHD hypokalemia HP were prevalent in COVID-19 patients.The significant low lymphocyte count, hypoproteinemia MESHD hypoproteinemia HP, hypokalemia MESHD hypokalemia HP, the persistent or worsen high CRP, high D-dimer, and high BNP, and the occurrence of hemoptysis MESHD hemoptysis HP and novel coronavirus (SARS-CoV-2) viremia MESHD viremia HP were important indicators for early diagnosis and prediction of severe disease progression MESHD. 2.Characteristic images of lung CT had a clear change in COVID - 19, Ground-glass opacity (GGO) and high-density linear combinations may indicate different pathological changes. Rapid lobular progression of GGO suggests the possibility of severe disease MESHD. 3.Basic principles of early intervention treatment of COVID-19: on the premise of no effective antiviral drugs, treatment is based on supportive and symptomatic therapy (albumin supplementation, supplement of potassium, supplement blood SERO plasma SERO, etc.) in order to maintain the stability of the intracellular environment and adequately reactivate body immunity to clean up SARS-CoV-2 . 4. According to severity, oxygenation index, body weight MESHD, age TRANS, underlying diseases MESHD, appropriate amount methylprednisolone application on severe/critical COVID-19 patients on demand, improved blood SERO oxygen and reduced the utilization rate of invasive mechanical ventilation, case fatality rate and medical burden significantly. The most common indications for invasive mechanical ventilation should be strictly control in critical COVID-19 patients. Conclusions: 1.Accurate and timely identification of clinical features in severe risks, and early and appropriate intervention can block disease progression MESHD. 2.Appropriate dose of methylprednisolone can effectively avoid invasive mechanical ventilation and reduce case fatality rate in critical COVID-19 patients.

    Acute liver injury and its association with death MESHD risk of patients with COVID-19: a hospital-based prospective case-cohort study

    Authors: Lin Fu; Jun Fei; Shen Xu; Hui-Xian Xiang; Ying Xiang; Zhu-Xia Tan; Meng-Die Li; Fang-Fang Liu; Ying Li; Ming-Feng Han; Xiu-Yong Li; Hui Zhao; De-Xiang Xu

    doi:10.1101/2020.04.02.20050997 Date: 2020-04-06 Source: medRxiv

    Background: Coronavirus disease MESHD 2019 (COVID-19) is a newly respiratory infectious disease MESHD caused by severe acute respiratory syndrome MESHD coronavirus-2 (SARS-CoV-2) with multiple organ injuries. The aim of this study was to analyze SARS-CoV-2-induced acute liver injury (ALI), its association with death MESHD risk and prognosis after discharge. Methods: Three-hundred and fifty-five COVID-19 patients were recruited. Clinical data were collected from electronic medical records. ALI was evaluated and its prognosis was tracked. The association between ALI and death MESHD risk was analyzed. Results: Of 355 COVID-19 patients, 211 were common, 88 severe, and 51 critical ill cases, respectively. On admission, 223 (62.8%) patients were with hypoproteinemia MESHD hypoproteinemia HP, 151(42.5%) with cholestasis MESHD cholestasis HP, and 101 (28.5%) with hepatocellular injury. As expected, ALI was more common in critical ill patients. By multivariate logistic regression, male TRANS, older age TRANS and lymphocyte reduction were three important independent risk factors predicting ALI among COVID-19 patients. Death MESHD risk analysis shows that fatality rate was higher among patients with hypoproteinemia MESHD hypoproteinemia HP than those without hypoproteinemia MESHD hypoproteinemia HP (RR=9.471, P<0.001). Moreover, fatality rate was higher among patients with cholestasis MESHD cholestasis HP than those without cholestasis MESHD cholestasis HP (RR=2.182, P<0.05). Follow-up observation found that more than one hepatic functional indexes of two-third patients remained abnormal 14 days after discharge. Conclusions: ALI at early stage elevates death MESHD risk of COVID-19 patients. SARS-CoV-2-induced ALI has not recovered completely 14 days after discharge.

    Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China

    Authors: Sha Fu; Xiaoyu Fu; Yang Song; Min Li; Pin-hua Pan; Tao Tang; Chunhu Zhang; Tiejian Jiang; Deming Tan; Xuegong Fan; Xinping Sha; Jingdong Ma; Yan Huang; Shaling Li; Yixiang Zheng; Zhaoxin Qian; Zeng Xiong; Lizhi Xiao; Huibao Long; Jianghai Chen; Yi Ouyang

    doi:10.1101/2020.04.03.20051763 Date: 2020-04-06 Source: medRxiv

    Background: The severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) has progressed to a pandemic associated with substantial morbidity and mortality. The WHO and the United States Center for Disease MESHD Control and Prevention (CDC) have issued interim clinical guidance for management of patients with confirmed coronavirus disease MESHD (COVID-19), but there is limited data on the virologic and clinical characteristics for prognosis of severe COVID-19. Methods: A total of 50 patients with severe COVID-19 were divided into good and poor recovery groups. The dynamic viral shedding and serological characteristics of SARS-CoV-2 were explored. The risk factors associated with poor recovery and lung lesion resolutions were identified. In addition, the potential relationships among the viral shedding, the pro-inflammatory response, and lung lesion evolutions were characterized. Results: A total of 58% of the patients had poor recovery and were more likely to have a prolonged interval of viral shedding. The longest viral shedding was 57 days after symptom onset TRANS. Older age TRANS, hyperlipemia, hypoproteinemia MESHD hypoproteinemia HP, corticosteroid therapy, consolidation on chest computed-tomography (CT), and prolonged SARS-CoV-2 IgM positive were all associated with poor recovery. Additionally, the odds of impaired lung lesion resolutions were higher in patients with hypoproteinemia MESHD hypoproteinemia HP, hyperlipemia, and elevated levels of IL-4 and ferritin. Finally, viral shedding and proinflammatory responses were closely correlated with lung lesion evolutions on chest CT. Conclusions Patients with severe COVID-19 have prolonged SARS-CoV-2 infection MESHD and delayed intermittent viral shedding. Older age TRANS, hyperlipemia, hypoproteinemia MESHD hypoproteinemia HP, corticosteroid usage, and prolonged SARS-CoV-2 IgM positive might be utilized as predicative factors for the patients with poor recovery.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.